Overview

Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)

Status:
Completed

Trial end date:
2019-07-30

Target enrollment:

Participant gender:

Summary

Evaluating the efficacy of vortioxetine 10 mg/day and 20 mg/day versus placebo on depressive symptoms in adolescents (age ≥12 and ≤17 years) with a DSM-5™ (Diagnostic and Statistical Manual of Mental Disorders, 5th edition) diagnosis of Major depressive disorder (MDD).

Phase:

Phase 3

Details

Lead Sponsor:

H. Lundbeck A/S

Collaborator:

Takeda

Treatments:

Fluoxetine
Vortioxetine